Know Cancer

or
forgot password

Nonmyeloablative Stem Cell Transplantation With or Without Lenalidomide for Chronic Lymphocytic Leukemia (RV-CLL-PI-0294)


Phase 2
18 Years
75 Years
Open (Enrolling)
Both
Chronic Lymphocytic Leukemia

Thank you

Trial Information

Nonmyeloablative Stem Cell Transplantation With or Without Lenalidomide for Chronic Lymphocytic Leukemia (RV-CLL-PI-0294)


The Study Drugs:

Lenalidomide is designed to change the body's immune system. It may also interfere with the
development of tiny blood vessels that help support tumor growth. Therefore, in theory, it
may decrease or prevent the growth of cancer cells.

Bendamustine is designed to damage and destroy the DNA (genetic material) of cancer cells.

Fludarabine is designed to make cancer cells less able to repair damaged DNA (the genetic
material of cells). This may increase the likelihood of the cells dying.

Rituximab is designed to attach to leukemia cells, which may cause them to die.

Study Treatment:

If you are found to be eligible to take part in this study, you will begin treatment within
30 days after the screening visit. All liquid study drugs will be given through a central
venous catheter (CVC) that will be left in place throughout treatment. A CVC is a sterile
flexible tube that will be placed into a large vein while you are under local anesthesia.
Your doctor will explain this procedure to you in more detail, and you will be required to
sign a separate consent form for this procedure.

On Days -13, -6, +1, and +8, you will receive rituximab over 5-7 hours by CVC.

On Days -5 to -3, you will receive fludarabine over 1 hour and bendamustine over 1 hour by
CVC. You will be given standard drugs such as hydrocortisone and Tylenol to help decrease
the risk of side effects. You may ask the study staff for information about how the drugs
are given and their risks.

On Days -2 to -1, if the donor is not related or is not completely matched, you will receive
thymoglobulin (ATG) over 4 hours by CVC. This will help to reduce the risk of your body
rejecting the transplant.

On Days -2 to -1, if the donor is related, you will "rest" (not receive chemotherapy).

On Day -2, you will start to receive tacrolimus by CVC to help prevent graft-versus-host
disease. This will be changed to a dose of tacrolimus by mouth, once you are discharged
from the hospital. You will continue to take tacrolimus by mouth for 6-8 months following
your transplant.

On Day 0, the blood stem cells that were collected from your donor will be transplanted
(given back to your body) through the CVC over 30-45 minutes.

On Days 1, 3, and 6 after the stem cell transplant (and Day 11 if the donor is not related
or not completely matched), you will receive methotrexate over 30-60 minutes by CVC to help
prevent graft-versus-host disease.

On Day 7 after the transplant, G-CSF (filgrastim) will be injected under your skin once a
day until your white blood cell counts recover. Filgrastim is designed to help increase the
number of white blood cells.

Treatment with Lenalidomide:

If your blood cell counts are high enough and if you have not experienced side effects,
between Days 90 and 100 after the transplant, you will be randomly assigned (as in the flip
of a coin) into 1 of 2 groups. If you are in Group 1 you will take lenalidomide in addition
to the treatment listed above. If you are in Group 2, you will not take lenalidomide.

If you are in Group 1, you will take lenalidomide 1 time every day for 3-12 months,
depending on the disease response to the treatment.

You should swallow lenalidomide capsules whole, with water, at the same time each day. Do
not break, chew, or open the capsules.

If you miss a dose of lenalidomide, take it as soon as you remember on the same day. If you
miss taking your dose for the entire day, take your regular dose the next scheduled day (do
NOT take double your regular dose to make up for the missed dose).

If you take more than the prescribed dose of lenalidomide you should seek emergency medical
care (if needed) and contact the study staff right away.

You will be given standard drugs such as aspirin, Coumadin (warfarin), heparin, and/or
allopurinol to help decrease the risk of side effects. You may ask the study staff for
information about how the drugs are given and their risks.

If the doctor thinks it is needed, your dose and schedule of lenalidomide will be changed.

If you are in Group 2, you will take no additional drugs.

Pregnancy Tests While Taking Lenalidomide:

Women who are able to become pregnant must have 2 negative pregnancy tests: the first test
within 10-14 days before lenalidomide is prescribed and the second test within 24 hours
before lenalidomide is prescribed. This blood test will be taken as part of a routine blood
draw. The prescription must be filled within 7 days.

Once a week for the first month you take lenalidomide, women who are able to become pregnant
will have blood (about 1 teaspoon) drawn for a pregnancy test. Then, in females with regular
menstrual cycles, blood (about 1 teaspoon) will be drawn for pregnancy testing every 4
weeks, at the end of study, and 28 days after the last dose of lenalidomide. If menstrual
cycles are irregular, blood (about 1 teaspoon) will be drawn every 2 weeks, at the end of
study, and 14 and 28 days after the last dose of lenalidomide.

Study Visits (both Groups):

You must stay in the Houston area for about 100 days after the stem cell transplant.

Between Days 25 and 35 and then about 3 months after the stem cell transplant:

- You will have a physical exam.

- You will have computed tomography (CT) scans to check the status of the disease.

- You will have positron emission tomography (PET) scan to check the status of the
disease, if the doctor thinks it is needed.

- Blood (about 2 tablespoons) will be drawn for routine tests and to check the level of
tacrolimus.

- You will have a bone marrow biopsy/aspirate to check the status of the disease.

Study Visits (Group 1):

If you are in Group 1, blood (about 2 tablespoons) will be drawn for routine tests weekly
until the maximum dose of lenalidomide is reached, then once every 2 weeks while you are
taking lenalidomide.

Follow-up:

Every 3 months during the first 18 months and then every 6 months up to 3 years:

- You will have a physical exam.

- You will have CT scans to check the status of the disease.

- You will have PET scans to check the status of the disease, if the doctor thinks it is
needed.

- Blood (about 2 tablespoons) will be drawn for routine tests.

- You will have a bone marrow biopsy to check the status of the disease.

Length of Study:

You will be on study up to about 3 years. You will be taken off study if the disease gets
worse or you experience any intolerable side effects.

End-of-Study Visit:

After you are off study, you will have an end-of-study visit:

- You will have a physical exam.

- You will have CT scans to check the status of the disease.

- You will have PET scans to check the status of the disease, if the doctor thinks it is
needed.

- Blood (about 2 tablespoons) will be drawn for routine tests.

- You will have a bone marrow biopsy to check the status of the disease.

This is an investigational study. All of the drugs used in this study are FDA approved and
commercially available for the treatment of CLL. The use of the drugs together in this study
is investigational.

Up to 80 patients will take part in this study. All will be enrolled at MD Anderson.


Inclusion Criteria:



1. Age 18-75 years at the time of signing the informed consent form.

2. Disease: CLL in relapse, after failing conventional chemo-antibody combination
therapy; CLL patients who failed to achieve CR with frontline conventional
chemo-antibody; CLL patients with 17p deletion; CLL in Richter's.

3. Able to adhere to the study visit schedule and other protocol requirements.

4. Donor: HLA compatible related (HLA-A,-B,-DRBI matched or with one-antigen mismatched)
or HLA compatible unrelated.

5. Eastern Cooperative Oncology Group (ECOG) performance status of
6. forced expiratory volume at one second (FEV1), forced vital capacity (FVC) and carbon
monoxide diffusing capacity (DLCO)>/= 40%.

7. Left ventricular ejection fraction (EF) > 40% with no uncontrolled arrhythmias or
symptomatic heart disease.

8. Serum creatinine
9. Serum glutamic pyruvic transaminase (SGPT) < 2 * upper limit of normal (ULN).

10. Voluntary signed, written IRB-approved informed consent before performance of any
study-related procedure not part of normal medical care, with the understanding that
consent may be withdrawn by the subject at any time without prejudice to future
medical care.

11. All previous cancer therapy, including radiation, hormonal therapy and surgery, must
have been discontinued at least 3 weeks prior to treatment in this study.

12. Disease free of prior malignancies for >/= 5 years with exception of currently
treated basal cell, squamous cell carcinoma of the skin, or carcinoma "insitu" of the
cervix or breast.

13. Females of childbearing potential (FCBP)† must have a negative serum or urine
pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to
study entry.

14. Disease must be chemosensitive (ie, patients must have PR or better based on CT
Scans, PET Scan, and bone marrow biopsy).

15. Patients suspected to have Richter's transformation (such as elevated LDH) and/or who
are PET positive, should have a lymph node biopsy to assess histological status of
the disease

16. Patients must be off of alemtuzumab for 6 weeks prior to consenting.

Exclusion Criteria:

1. Any serious medical condition, laboratory abnormality, or psychiatric illness that
would prevent the subject from signing the informed consent form.

2. Pregnant or breast feeding females. (Lactating females must agree not to breast feed
while taking lenalidomide).

3. Any condition, including the presence of laboratory abnormalities, which places the
subject at unacceptable risk if he/she were to participate in the study or confounds
the ability to interpret data from the study.

4. Use of any other experimental drug or therapy within 28 days of baseline.

5. Known hypersensitivity to thalidomide, lenalidomide, bendamustine, fludarabine. For
patients will unrelated donors: Known hypersensitivity to thymoglobulin.

6. The development of erythema nodosum if characterized by a desquamating rash while
taking thalidomide or similar drugs.

7. Concurrent use of other anti-cancer agents or treatments.

8. Known positive for HIV or infectious hepatitis, type A, B or C.

9. Sinuses should be evaluated by either CT neck or CT sinuses to exclude infections

10. Deep-vein thrombosis or pulmonary embolism within 3 months of study entry.

11. History of serious infection requiring hospitalization within the last 3 months of
consenting.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Number of Patients Needing Immunomanipulation within 18 months after non-myeloablative allogeneic transplantation for CLL with or without lenalidomide maintenance

Outcome Time Frame:

18 months

Safety Issue:

No

Principal Investigator

Issa F. Khouri, MD, BS

Investigator Role:

Study Chair

Investigator Affiliation:

UT MD Anderson Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

2007-0871

NCT ID:

NCT00899431

Start Date:

May 2009

Completion Date:

Related Keywords:

  • Chronic Lymphocytic Leukemia
  • Nonmyeloablative Stem Cell Transplantation
  • Chronic Lymphocytic Leukemia
  • CLL
  • Immunomanipulation
  • Fludarabine
  • Lenalidomide
  • Rituximab
  • Thymoglobulin
  • Stem Cell Transplantation
  • Leukemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid

Name

Location

UT MD Anderson Cancer CenterHouston, Texas  77030